Form 4: Lifevantage Director Reports Planned Stock Transactions

Lifevantage Corp Director Michael A. Beindorff reported planned acquisitions and dispositions of common stock, including a grant and tax-related sales.

Summary

• Michael A. Beindorff, a Director of Lifevantage Corp (LFVN), reported planned transactions involving the company's common stock.
• On November 6, 2025, Mr. Beindorff is scheduled to acquire 13,531 shares of common stock at a price of $7.76 per share.
• These acquired shares are part of the issuer's outside director compensation program and are set to vest in a single installment on November 6, 2026, contingent on continuous service.
• On November 7, 2025, Mr. Beindorff is scheduled to dispose of 1,000 shares of common stock at $7.33 per share.
• Also on November 7, 2025, he is scheduled to dispose of an additional 35,000 shares of common stock at a weighted average price of $6.9215, with individual sales ranging from $6.65 to $7.40.
• A portion of the 35,000 shares sold are intended to cover tax obligations associated with the vesting of a restricted stock award.
• Following these planned transactions, Mr. Beindorff's direct beneficial ownership will be 35,389 shares.
• Indirect beneficial ownership includes 56,413 shares held by the Michael A. Beindorff Trust, 126 shares by his spouse as custodian for minor children, and 5,500 shares by his spouse.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions, including a stock grant and sales, some of which are for tax obligations. This is a neutral event, as it reflects pre-planned activity rather than new operational or financial news.

Positives

• The reporting person is scheduled to acquire 13,531 shares of common stock as part of the company's outside director compensation program, indicating continued alignment with shareholder interests.

Negatives

• The reporting person is scheduled to dispose of a total of 36,000 shares of common stock, with a significant portion (35,000 shares) sold at a weighted average price of $6.9215.
• A portion of the shares sold are explicitly stated to cover tax obligations, which is a common reason for insider sales but still represents a reduction in direct holdings.

Future Outlook

The filing details planned future transactions under a Rule 10b5-1 plan, including a stock grant vesting in November 2026 and sales scheduled for November 2025. These transactions reflect pre-arranged activities rather than new forward-looking guidance on company performance.

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions, common across all publicly traded companies. It reflects a director's pre-planned equity movements, which are typically executed under Rule 10b5-1 plans to avoid accusations of trading on material non-public information. Such filings are standard for directors and executives managing their personal equity holdings.

Comparison to Industry Standards

• The use of a Rule 10b5-1 plan for these transactions aligns with best practices for corporate insiders to manage their stock holdings while adhering to SEC regulations and avoiding insider trading concerns. This is a standard mechanism widely adopted by executives and directors across various industries.
• The grant of shares as part of an outside director compensation program is a common practice in corporate governance, aligning director incentives with shareholder value, comparable to compensation structures at companies like Herbalife Nutrition Ltd. (HLF) or USANA Health Sciences, Inc. (USNA) within the direct selling or health and wellness sectors.

Related Party Transactions

• Indirect beneficial ownership includes shares held by the Michael A. Beindorff Trust U/A DTD 06/14/2000, of which the reporting person and his spouse are trustees.

Stakeholder Impact

• Shareholders may view the director's planned stock sales, even if for tax purposes, as a slight reduction in direct insider alignment, though the concurrent stock grant partially offsets this.
• The transactions are part of a pre-arranged plan, which generally minimizes immediate market impact compared to unplanned insider trading.

Next Steps

• The 13,531 shares acquired on November 6, 2025, are expected to vest in a single installment on November 6, 2026, subject to continuous service.

Key Dates

Recommendation

The filing details routine insider transactions, including a stock grant and sales, some of which are for tax obligations. While the sales reduce direct holdings, the grant indicates continued alignment. These pre-planned transactions under a 10b5-1 plan are generally not indicative of a significant shift in company fundamentals or management's long-term view, thus a 'hold' recommendation is appropriate as this filing alone does not provide a strong signal for a 'buy' or 'sell' decision.

Keywords

Lifevantage Corp, LFVN, Form 4, Insider Trading, Director Stock Transactions, Stock Grant, Stock Sale, Beneficial Ownership, 10b5-1 Plan